All In Biotech

Drug Trial Radar · NCT05296629

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.

Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

323

Actual

Start

Mar 14, 2022

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Journey Medical CorporationIndustry
Sponsor type
Industry
Collaborators
Dr. Reddy's Laboratories Limited, India
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.

Conditions

  • Papulopustular Rosacea

Interventions

  • DFD-29Drug

    DFD-29 (40 mg) extended release capsules

  • DoxycyclineDrug

    Doxycycline 40 mg capsules

  • PlaceboDrug

    Placebo capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.Time frame: Baseline to Week 16.
  2. Change in Total Inflammatory Lesion Count Compared to Placebo.Time frame: Baseline to Week 16.

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site 05

    Rogers, Arkansas

  • Clinical Trial Site 10

    Cerritos, California

  • Clinical Trial Site 03

    Fremont, California

  • Clinical Trial Site 25

    San Diego, California

  • Clinical Trial Site 29

    San Diego, California

  • Clinical Trial Site 11

    Clearwater, Florida

  • Clinical Trial Site 08

    Coral Gables, Florida

  • Clinical Trial Site 22

    Coral Gables, Florida

  • Clinical Trial Site 02

    Indianapolis, Indiana

  • Clinical Trial Site 27

    Overland Park, Kansas

  • Clinical Trial Site 09

    Brighton, Massachusetts

  • Clinical Trial Site 18

    Ann Arbor, Michigan

  • Clinical Trial Site 28

    Warren, Michigan

  • Clinical Trial Site 21

    New Brighton, Minnesota

  • Clinical Trial Site 15

    Las Vegas, Nevada

  • Clinical Trial Site 24

    New York, New York

  • Clinical Trial Site 17

    High Point, North Carolina

  • Clinical Trial Site 04

    Wilmington, North Carolina

  • Clinical Trial Site 06

    Beachwood, Ohio

  • Clinical Trial Site 01

    Sugarloaf, Pennsylvania

  • Clinical Trial Site 19

    East Greenwich, Rhode Island

  • Clinical Trial Site 23

    Nashville, Tennessee

  • Clinical Trial Site 20

    College Station, Texas

  • Clinical Trial Site 13

    Houston, Texas

  • Clinical Trial Site 07

    Plano, Texas

  • Clinical Trial Site 26

    San Antonio, Texas

  • Clinical Trial Site 12

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.